About: Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection
Creator	Wang, Kai Chen, Juan Hu, Jie Deng, Hai-Jun Hu, Jie-Li Huang, Ai-Long Long, Quan-Xin Tang, Ni Gao, Qing-Zhu He, Chang-Long Huang, Lu-Yi Zhang, Gui-Ji
Source	MedRxiv
abstract	Background Coronavirus disease 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of SARS-CoV-2-specific neutralizing antibodies (NAbs) in COVID-19 patients. Methods Blood samples (n=173) were collected from 30 COVID-19 patients over a 3-month period after symptom onset and analyzed for SARS-CoV-2-specific NAbs, using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines. Results SARS-CoV-2-specific NAb titers were low for the first 7-10 d after symtom onset and increased after 2-3 weeks. The median peak time for NAbs was 33 d (IQR 24-59 d) after symptom onset. NAb titers in 93.3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34.8% (IQR 19.6-42.4%). NAb titers increased over time in parallel with the rise in IgG antibody levels, correlating well at week 3 (r = 0.41, p < 0.05). The NAb titers also demonstrated a significant positive correlation with levels of plasma proinflammatory cytokines, including SCF, TRAIL, and M-CSF. Conclusions These data provide useful information regarding dynamic changes in NAbs in COVID-19 patients during the acute and convalescent phases.
has issue date	2020-07-17(xsd:dateTime)
bibo:doi	10.1101/2020.07.14.20151159
has license	medrxiv
sha1sum (hex)	afcfaacdcbcde35e2be7365e71e8a395287a53c6
schema:url	https://doi.org/10.1101/2020.07.14.20151159
resource representing a document's title	Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection
resource representing a document's body	covid:afcfaacdcbcde35e2be7365e71e8a395287a53c6#body_text
is schema:about of	named entity 'onset' named entity 'licensed' named entity 'Little' named entity 'global' named entity 'titers' named entity 'neutralizing antibody' named entity '2-3' named entity 'TRAIL' named entity 'therapy' named entity 'COVID-19' named entity 'titers' named entity 'time' named entity 'patients' named entity 'correlation' named entity 'collected' named entity 'levels' named entity 'levels' named entity 'NAb' named entity 'specific' named entity 'infection' named entity 'plasma' named entity 'positive correlation' named entity 'symptom' named entity 'M-CSF' named entity 'SARS-CoV-2' named entity 'neutralizing antibody' named entity 'CC-BY-NC-ND 4.0' named entity 'NAb' named entity 'preprint' named entity 'memory T cells' named entity 'SARS-CoV' named entity 'nucleocapsid' named entity 'antibody therapy' named entity 'TRAIL' named entity 'COVID' named entity 'NAb' named entity 'SARS-CoV-2' named entity 'memory T cells' named entity 'serological' named entity 'virus' named entity 'medRxiv' named entity 'ACE-2' named entity 'titer' named entity 'IgG' named entity 'medRxiv' named entity 'preprint' named entity 'antibodies' named entity 'serum' named entity 'CC-BY-NC-ND 4.0' named entity 'SARS-CoV-2' named entity 'positively correlated' named entity 'nucleocapsid' named entity 'humoral immune response' named entity 'peer review' named entity 'COVID' named entity 'Wuhan University' named entity 'SARS-CoV-2' named entity 'ID50' named entity 'infection' named entity 'follow-up' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'antigen' named entity 'enzyme' named entity 'Virus' named entity 'antiviral' named entity 'SARS-CoV-2' named entity 'pathogenesis' named entity 'preprint' named entity 'positively correlated' named entity 'SARS-CoV' named entity 'blood samples' named entity 'cytotoxicity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software